Loading...
NPI 1710105010 · Seattle, WA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
University Of Washington is a clinical medical laboratory provider located in Seattle, Washington. This profile covers 238 Medicare and 195 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | University Of Washington |
| Address | 1959 Ne Pacific St |
| City | Seattle |
| State | WA |
| ZIP | 98195 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | April 23, 2007 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $36.6M |
| Medicare | $1.5M |
University of Washington is a long-established clinical medical laboratory with an NPI enumerated 2007-04-23 (~19 years ago), indicating nearly two decades of billing activity and an institutional presence capable of handling high-volume specimen processing and specialty tests. The mix of codes reported — routine panels (80061, 80053), infectious disease PCRs (U0003, U0005), and proprietary testing (0058U) — is consistent with an academic or reference lab that supports both large-scale public health testing and niche, research-oriented assays.
Medicaid revenue dominates this provider’s public-payer mix: total Medicaid revenue is $36.6M versus total Medicare revenue of $1.5M, so the provider is effectively Medicaid-dominant in scale and operations for the period on file. This imbalance is reflected in Medicaid claim counts and revenue concentration around pandemic-era testing codes.
Revenue concentration differs sharply by payer: for Medicare the top 3 codes account for 32.0% of Medicare revenue (top Medicare drivers are U0003, 80061, 80053), indicating a moderate concentration in a mix of COVID testing and routine lab panels. By contrast, the top 3 Medicaid codes account for 84.5% of Medicaid revenue (U0003, G2023, G0481), signaling extreme dependence on a very small set of services for Medicaid earnings, primarily SARS-CoV-2 testing and related specimen collection and definitive drug testing.
On Medicaid the provider is a statewide outlier for SARS-CoV-2 testing: U0003 generated 428.5K claims and $26.6M revenue (77.1% of the provider’s Medicaid revenue) and ranks #1 of 103 in-state (100th percentile; extreme outlier). G2023 also ranks #1 in-state with 74.8K claims and $1.3M revenue (3.9% of Medicaid revenue) and is similarly labeled an extreme outlier, together indicating the lab functions as a principal in-state COVID testing and specimen-collection center for Medicaid patients.
Medicare volumes show a different competitive stance: U0003 is present on Medicare but ranks #134 of 973 nationally (86th percentile) and is described as typical, unremarkable volume; routine panel codes such as 80061 and 80053 show very high national percentiles (99th) but are characterized in the data as typical volumes for large reference labs. Overall, the provider appears nationally active on common lab panels but not uniquely dominant on Medicare for pandemic-era testing.
The presence of PLA code 0058U (Merkel SmT Oncoprotein Antibody Titer) with 153 Medicare claims and $48.5K revenue — and a national rank of #1 of 2 providers (100th percentile) — points to specialized, institution-specific testing capability consistent with an academic laboratory that performs proprietary assays alongside high-throughput routine testing. This suggests research/tertiary care linkages and the ability to bill for unique diagnostic services at the Medicare level.
Definitive drug-testing codes (G0481 on Medicare and G0481/G0480 on Medicaid) and high-volume presumptive drug screens (80307) appear throughout both payers’ lists, indicating a substantive toxicology services line supporting justice, behavioral health, or substance-use treatment programs. On Medicaid, G0481 contributed $1.2M (3.5% of Medicaid revenue) and ranks #7 of 31 in-state (80th percentile), which signals meaningful but not exclusive market share in definitive drug testing within Washington.
Operational scale is underscored by extremely large Medicaid claim counts for pandemic testing (428.5K claims for U0003 and 74.8K claims for G2023), implying significant specimen logistics, high-throughput instrumentation, and processes for mass testing. Taken together with routine panel volumes reported on Medicare (many codes at high national percentiles), the billing mix reflects a dual role: a statewide hub for public-health testing and a high-capacity reference lab for standard clinical chemistry and hematology services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
238 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1,750 | $70 | $129.6K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 7,690 | $10 | $100K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 9,570 | $10 | $95.7K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 5,800 | $20 | $92.7K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 630 | $100 | $65.1K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 6,320 | $10 | $50.5K |
| 0058U | This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report code 0058U for… | 150 | $320 | $48.5K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 1,730 | $30 | $43.3K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 1,440 | $30 | $41.6K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 640 | $60 | $38.9K |
Showing 1–10 of 238
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 238 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
195 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 428,490 | $60 | $26.6M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 74,830 | $20 | $1.3M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 14,530 | $80 | $1.2M |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 22,440 | $30 | $762.8K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 22,430 | $30 | $762.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 9,690 | $50 | $465.2K |
| 87389 | The lab analyst performs a test to screen for human immunodeficiency virus, called HIV. The test screens for antigens of the HIV 1 virus and antibodies to the HIV 1 and HIV 2 viruses using an… | 15,850 | $20 | $317K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 22,960 | $10 | $298.4K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 10,950 | $30 | $295.6K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 32,430 | $10 | $291.8K |
Showing 1–10 of 195
How this provider's Medicaid billing volume and revenue compare to other Washington providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Washington median
195 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 7 | 30 | 660 | $100 | $1.5M |
| 81420 | The lab analyst performs a genomic sequence analysis panel to evaluate circulating cell free fetal DNA in maternal blood for genetic sequences of at least the genes on chromosomes 13, 18, and 21,… | 8 | 10 | 130 | $370 | $1.3M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 100 | 1,940 | $70 | $1M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 39 | 170 | 2,120 | $40 | $779.1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 33 | 90 | 1,760 | $50 | $601.4K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 19 | 20 | 1,110 | $130 | $509.9K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 7 | 120 | 2,040 | $30 | $464.9K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 7 | 120 | 2,020 | $30 | $441.1K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 7 | 90 | 1,030 | $30 | $246.3K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 19 | 60 | 1,340 | $30 | $208.1K |
Showing 1–10 of 195
Other providers in the same ZIP code as University Of Washington, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Carrie Marder | WA | Neuroradiology Physician | $513.5K | $0 |
| Sarah Anderson | WA | Diagnostic Radiology Physician | $360.6K | $0 |
| Annemarie Shepherd | WA | Radiation Oncology Physician | $335.3K | $0 |
| Courtney Gwinn | WA | Dermatology Physician | $319.7K | $0 |
| Reza Masoomi | WA | Interventional Cardiology Physician | $319.1K | $0 |
| Jean Lee | WA | Body Imaging Physician | $248.1K | $0 |
| Patrick Goleski | WA | Interventional Cardiology Physician | $239.9K | $0 |
| Katelan Longfellow | WA | Neurology Physician | $221.6K | $0 |
| Larry Cai | WA | Diagnostic Radiology Physician | $207.8K | $0 |
| Gabriel Aldea | WA | Thoracic Surgery (Cardiothoracic Vascular Surgery) Physician | $198.7K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.